Cargando…

Vaccine market and production capabilities in the Americas

In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals’ d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortiz-Prado, Esteban, Espín, Estefanía, Vásconez, Jorge, Rodríguez-Burneo, Nathalia, Kyriakidis, Nikolaos C., López-Cortés, Andrés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042620/
https://www.ncbi.nlm.nih.gov/pubmed/33849635
http://dx.doi.org/10.1186/s40794-021-00135-5
_version_ 1783678156228526080
author Ortiz-Prado, Esteban
Espín, Estefanía
Vásconez, Jorge
Rodríguez-Burneo, Nathalia
Kyriakidis, Nikolaos C.
López-Cortés, Andrés
author_facet Ortiz-Prado, Esteban
Espín, Estefanía
Vásconez, Jorge
Rodríguez-Burneo, Nathalia
Kyriakidis, Nikolaos C.
López-Cortés, Andrés
author_sort Ortiz-Prado, Esteban
collection PubMed
description In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals’ distribution and production. Some Latin American countries rank in the top 20 of worldwide vaccine manufacturers, with Cuba, Brazil, México and Colombia have a self-sufficient vaccine production of 72.7%, 54,2%; 25%; and 7.7%, respectively, of the national vaccine demand. On the other hand, the rest of Latin American countries cannot satisfy their demand for vaccines, and most of their efforts are associated with the distribution within their health systems rather than in transferring technology. Based on this literature review, the results suggest an increasing growth vaccine demand, not only for their growing populations and previously established demand but also for the recently exerted pressure due to the COVID-19 pandemic. Because the American continent has a marked inequality between the hegemonic producers of vaccines, the exporters, and those that depend heavily on importing these products, this could assert technological dependence in countries with rapid population growth and jeopardize the effectiveness of the two vaccination plans.
format Online
Article
Text
id pubmed-8042620
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80426202021-04-13 Vaccine market and production capabilities in the Americas Ortiz-Prado, Esteban Espín, Estefanía Vásconez, Jorge Rodríguez-Burneo, Nathalia Kyriakidis, Nikolaos C. López-Cortés, Andrés Trop Dis Travel Med Vaccines Review In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals’ distribution and production. Some Latin American countries rank in the top 20 of worldwide vaccine manufacturers, with Cuba, Brazil, México and Colombia have a self-sufficient vaccine production of 72.7%, 54,2%; 25%; and 7.7%, respectively, of the national vaccine demand. On the other hand, the rest of Latin American countries cannot satisfy their demand for vaccines, and most of their efforts are associated with the distribution within their health systems rather than in transferring technology. Based on this literature review, the results suggest an increasing growth vaccine demand, not only for their growing populations and previously established demand but also for the recently exerted pressure due to the COVID-19 pandemic. Because the American continent has a marked inequality between the hegemonic producers of vaccines, the exporters, and those that depend heavily on importing these products, this could assert technological dependence in countries with rapid population growth and jeopardize the effectiveness of the two vaccination plans. BioMed Central 2021-04-13 /pmc/articles/PMC8042620/ /pubmed/33849635 http://dx.doi.org/10.1186/s40794-021-00135-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Ortiz-Prado, Esteban
Espín, Estefanía
Vásconez, Jorge
Rodríguez-Burneo, Nathalia
Kyriakidis, Nikolaos C.
López-Cortés, Andrés
Vaccine market and production capabilities in the Americas
title Vaccine market and production capabilities in the Americas
title_full Vaccine market and production capabilities in the Americas
title_fullStr Vaccine market and production capabilities in the Americas
title_full_unstemmed Vaccine market and production capabilities in the Americas
title_short Vaccine market and production capabilities in the Americas
title_sort vaccine market and production capabilities in the americas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042620/
https://www.ncbi.nlm.nih.gov/pubmed/33849635
http://dx.doi.org/10.1186/s40794-021-00135-5
work_keys_str_mv AT ortizpradoesteban vaccinemarketandproductioncapabilitiesintheamericas
AT espinestefania vaccinemarketandproductioncapabilitiesintheamericas
AT vasconezjorge vaccinemarketandproductioncapabilitiesintheamericas
AT rodriguezburneonathalia vaccinemarketandproductioncapabilitiesintheamericas
AT kyriakidisnikolaosc vaccinemarketandproductioncapabilitiesintheamericas
AT lopezcortesandres vaccinemarketandproductioncapabilitiesintheamericas